Today: 9 June 2026
Starbucks stock slips after hours as Investor Day looms and a top broker turns bullish
23 January 2026
1 min read

Starbucks stock slips after hours as Investor Day looms and a top broker turns bullish

New York, Jan 22, 2026, 20:07 EST — Market closed.

  • After the close, Starbucks shares dipped roughly 0.6%, as attention turned back to its events from late January
  • The company scheduled its Investor Day for Jan. 29, with executives ready to unveil a long-term growth plan
  • William Blair raised its rating on the stock just before Starbucks’ earnings report due Jan. 28

Starbucks (SBUX) shares dipped roughly 0.6% to $95.83 after Thursday’s close, with investors bracing for a packed schedule featuring earnings next week and a strategy update the following day.

The timing is critical. With earnings scheduled for Jan. 28 and an Investor Day the next day, Jan. 29, traders often shift positions ahead of time—especially in a stock where guidance and long-term targets can swiftly alter estimates.

Investor Day usually serves as a platform for a company to lay out its plans on growth, spending, and returns — sometimes shifting expectations within hours. For Starbucks, the focus is on traffic trends, cost pressures, and the pace at which margins might bounce back.

Starbucks plans to lay out its long-term growth roadmap at its 2026 Investor Day on Thursday, Jan. 29. CEO Brian Niccol and CFO Cathy Smith, along with other executives, will lead presentations and a Q&A session.

The company said the webcast will kick off around 8:00 a.m. ET and continue until roughly midday.

William Blair raised its rating on Starbucks to “Outperform” from “Market Perform” on Thursday, citing anticipated domestic comparable-sales growth in the December quarter, Investing.com reports. https://www.investing.com/news/analyst-rat…

Comparable sales — a key metric — track sales at stores open for at least a year, giving investors insight into true demand beyond just new store openings.

Despite the upgrade, questions linger. William Blair highlighted margin recovery as a key issue, pointing out that rising labor costs could pressure profits if sales don’t rise accordingly, the report noted.

During regular U.S. trading on Thursday, Starbucks’ shares fluctuated between $94.92 and $97.76, ending with indications just under the previous close of $96.46.

The downside is clear: weaker-than-expected demand in next week’s results or cautious management commentary could weigh on the stock. And if the company outlines a strategy lacking clear cost and return targets, the share price might face pressure heading into the February reporting season.

Investors have their eyes on the calendar now. Starbucks will report its fiscal first-quarter results at 7:45 a.m. ET on Wednesday, Jan. 28, followed by a conference call at 8:00 a.m. ET, the company confirmed.

Stock Market Today

  • AmpliTech Shares Surge 26.7% on 5G Open RAN Testing Update
    June 9, 2026, 9:16 AM EDT. AmpliTech (AMPG) shares surged 26.7% to $6.57 following its Open RAN testing update at the O-RAN Alliance Global PlugFest Spring 2026. The company's 64T64R Massive MIMO radio, which uses multiple antennas to enhance wireless capacity, was the only one of its kind tested with equipment from major operators including AT&T and Deutsche Telekom. Despite the strong test results, no new sales orders were announced, leaving investors cautious about future revenue impact. AmpliTech reported a 48.6% increase in first-quarter revenue to $5.35 million but remains unprofitable, narrowing its net loss to $1.52 million. The firm holds $18.4 million in cash and securities. Open RAN aims to enable multi-vendor interoperability in 5G networks, a critical push in telecom infrastructure modernization.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Why Arista Networks stock jumped 9% today — and what could move ANET next
Previous Story

Why Arista Networks stock jumped 9% today — and what could move ANET next

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week
Next Story

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week

Go toTop